Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia

Annals of Internal Medicine

Volumn 165, Issue 3, 2016, Pages 161-166

  Dahlén, Torsten ^a,b,c,d   Edgren, Gustaf ^a,b,c,d   Lambe, Mats ^a,b,c,d   Höglund, Martin ^a,b,c,d   Björkholm, Magnus ^a,b,c,d   Sandin, Fredrik ^a,b,c,d   Själander, Anders ^a,b,c,d   Richter, Johan ^a,b,c,d   Olsson Strömberg, Ulla ^a,b,c,d   Ohm, Lotta ^a,b,c,d   Bäck, Magnus ^a,b,c,d   Stenke, Leif ^a,b,c,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ADULT; ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWEDEN; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84980347521     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2306     Document Type: Article

References (25)

1. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-61. [PMID: 19282833] doi:10.1038/leu.2009.38
2. Hö glund M, Sandin F, Hellström K, Bjö reman M, Bjö rkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284-92. [PMID: 23843494] doi:10.1182/blood-2013-04-495598
3. Bjö rkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjö berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514-20. [PMID: 21576640] doi:10.1200/JCO.2011.34.7146
4. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197-203. [PMID: 22699418] doi:10.1038/leu.2012.134
5. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120:3898-905. [PMID: 22915637] doi:10.1182/blood-2012-02-410688
6. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507-13. [PMID: 25037629] doi:10.1182/blood-2014-05-579136
7. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013; 27:1316-21. [PMID: 23459449] doi:10.1038/leu.2013.70
8. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310-5. [PMID: 23459450] doi:10.1038/leu.2013.69
9. Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study [Letter]. Eur J Haematol. 2013;90:531-2. [PMID: 23506097] doi:10.1111/ejh.12096
10. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533-9. [PMID: 21538470] doi:10.1002/ajh.22037
11. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, et al. Severe peripheral arterial disease during nilotinib therapy [Letter]. J Natl Cancer Inst. 2011;103:1347-8. [PMID: 21813414] doi:10.1093/jnci/djr292
12. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337-40. [PMID: 22633167] doi:10.1016/j.clml.2012.04.005
13. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369: 1783-96. [PMID: 24180494] doi:10.1056/NEJMoa1306494
14. U.S. Food and Drug Administration. Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. 31 October 2013 [updated 5 November 2013]. Accessed at www.fda.gov/Drugs/DrugSafety/ucm379554.htm on 27 March 2015.
15. Hö glund M, Bjö reman M, Bjö rkholm M, Brune M, Ekblom M, Hellström K, et al. Real world data on chronic myeloid leukemia: a report from the Swedish population based CML-registry [Abstract]. Haematologica. 2010;95:337.
16. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659-67. [PMID: 19504049] doi:10.1007/s10654-009-9350-y
17. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. [PMID: 21658213] doi:10.1186/1471-2458-11-450
18. Wettermark B, Hammar N, Fored CM, MichaelFored C, Leimanis A, Otterblad Olausson P, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-35. [PMID: 16897791]
19. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122: 872-84. [PMID: 23803709] doi:10.1182/blood-2013-05-501569
20. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014;12:1590-610. [PMID: 25361806]
21. Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40:348-58. [PMID: 24610470] doi:10.1055/s-0034-1370794
22. Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, et al. Early onset hypercholesterolemia induced by the 2ndgeneration tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99:1197-203. [PMID: 24658819] doi:10.3324/haematol.2014.104075
23. Breccia M, Muscaritoli M, Gentilini F, Latagliata R, Carmosino I, Rossi Fanelli F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib [Letter]. Leuk Res. 2007;31:1770-2. [PMID: 17382388]
24. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109:4686-92. [PMID: 17317858]
25. Breccia M, Molica M, Zacheo I, Serrao A, Alimena G. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol. 2015;94:393-7. [PMID: 25304102] doi:10.1007/s00277-014-2231-9